Lavifent

Fentanyl, the active ingredient in Lavifent, is an opioid analgesic presented as a transdermal patch for transdermal use. It provides continuous systemic delivery of fentanyl for the management of severe chronic pain, cancer‑related pain, and breakthrough pain in patients who require around‑the‑clock opioid therapy.

GNH USA supplies Lavifent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Lavifent (fentanyl) acts on the central opioid pathway to relieve intense pain.

Severe chronic pain: provides continuous opioid analgesia for patients with persistent severe pain. Cancer pain: delivers steady fentanyl levels to manage pain associated with malignancies. Breakthrough pain: offers rapid supplemental relief when breakthrough episodes occur despite baseline therapy. Post‑operative pain: can be used in selected cases for extended analgesia after major surgery.

Lavifent may cause a range of adverse reactions, varying from mild to life‑threatening.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dizziness - Dry mouth - Sweating

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Adrenal insufficiency - Seizures - Stevens‑Johnson syndrome - Opioid dependence or abuse

When prescribing or using Lavifent, several precautions should be observed to minimize risk. - Assess opioid tolerance: evaluate patient’s prior opioid exposure before initiating therapy. - Respiratory status: avoid use in patients with severe respiratory depression or compromised ventilation. - Monitor for addiction: regularly assess signs of misuse, dependence, or aberrant behavior. - Skin condition: do not apply the patch to broken, irritated, or infected skin. - Concurrent CNS depressants: use caution when combined with other sedatives or alcohol. - Store at room temperature: keep in original pouch, protect from light and moisture.

Lavifent can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Concomitant use with other central nervous system depressants (e.g., benzodiazepines, barbiturates) may cause profound respiratory depression. - Monoamine oxidase inhibitors (MAOIs) can increase opioid toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) raise fentanyl plasma levels. - Alcohol consumption intensifies sedative effects and respiratory risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce fentanyl concentrations, decreasing analgesia. - Other opioids or opioid agonists can increase cumulative opioid effect. - Anticholinergic agents may worsen constipation. - Diuretics may potentiate hypotensive effects.